Savara price target raised to $16 from $7 at Piper Sandler
PremiumThe FlySavara price target raised to $16 from $7 at Piper Sandler
9M ago
A New Cause for Concern: CymaBay Therapeutics Inc Adds a New Corporate Activity and Growth Risk
Premium
Company Announcements
A New Cause for Concern: CymaBay Therapeutics Inc Adds a New Corporate Activity and Growth Risk
9M ago
CymaBay reports Q4 EPS (35c), consensus (31c)
Premium
The Fly
CymaBay reports Q4 EPS (35c), consensus (31c)
9M ago
CymaBay downgraded to Market Perform from Outperform at LifeSci Capital
PremiumThe FlyCymaBay downgraded to Market Perform from Outperform at LifeSci Capital
9M ago
CymaBay downgraded to Neutral from Buy at UBS
Premium
The Fly
CymaBay downgraded to Neutral from Buy at UBS
9M ago
CymaBay downgraded to Neutral from Overweight at Piper Sandler
Premium
The Fly
CymaBay downgraded to Neutral from Overweight at Piper Sandler
9M ago
CymaBay downgraded to Neutral from Overweight at Cantor Fitzgerald
PremiumThe FlyCymaBay downgraded to Neutral from Overweight at Cantor Fitzgerald
9M ago
CymaBay downgraded to Hold from Buy at JonesResearch
Premium
The Fly
CymaBay downgraded to Hold from Buy at JonesResearch
9M ago
Gilead acquisition of CymaBay makes sense, says Wells Fargo
Premium
The Fly
Gilead acquisition of CymaBay makes sense, says Wells Fargo
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100